The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 24, 2018

Filed:

Jan. 19, 2015
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Justin Scot Hanes, Baltimore, MD (US);

Peter Anthony Campochiaro, Baltimore, MD (US);

Jie Fu, Baltimore, MD (US);

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/704 (2006.01); A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 47/50 (2017.01); A61K 47/48 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48215 (2013.01); A61K 9/0048 (2013.01); A61K 9/14 (2013.01); A61K 9/16 (2013.01); A61K 31/704 (2013.01); A61K 47/488 (2013.01); A61K 47/48192 (2013.01); A61K 47/50 (2017.08);
Abstract

Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.


Find Patent Forward Citations

Loading…